tetano
Editor, Senior Moderator
Clin Rheumatol. 2020 May 14. doi: 10.1007/s10067-020-05160-x. [Epub ahead of print]
COVID-19 with rheumatic diseases: a report of 5 cases.
Cheng C[SUP]1[/SUP], Li C[SUP]1[/SUP], Zhao T[SUP]1[/SUP], Yue J[SUP]1[/SUP], Yang F[SUP]2[/SUP], Yan Y[SUP]3,[/SUP][SUP]4,[/SUP][SUP]5[/SUP], Liu X[SUP]6,[/SUP][SUP]7[/SUP].
Author information
Abstract
The coronavirus disease 2019 (COVID-19), the result of an infection with the new virus, SARS-CoV-2, is rapidly spreading worldwide. It is largely unknown whether the occurrence of COVID-19 in patients with rheumatic immune diseases has some specific manifestations, or makes them more prone to rapidly progress into severe COVID-19. In this case report, we describe the clinical features of 5 rheumatic immune disease patients with the concomitant presence of COVID-19. Amongst these patients, 4 had rheumatoid arthritis (RA) and 1 had systemic sclerosis (SSc). Two patients had a history of close contact with a COVID-19 patient. The age of the patients ranged between 51 and 79 years. Fever (80%), cough (80%), dyspnea (40%), and fatigue (20%) were the most common presenting symptoms. Laboratory investigations revealed leukopenia and lymphopenia in 2 patients. In all the patients, chest computerized tomography (CT) revealed patchy ground glass opacities in the lungs. During the hospital stay, the condition of two patients remained the same (i.e., mild COVID-19), two patients progressed to the severe COVID-19, and one patient worsened to the critically ill COVID-19. These patients were treated with antiviral agents for COVID-19, antibiotics for secondary bacterial infections, and immunomodulatory agents for rheumatic immune diseases. All the patients responded well, were cured of COVID-19, and subsequently discharged.
KEYWORDS:
COVID-19; Coronavirus; Rheumatic immune disease; SARS-CoV-2
PMID:32406001DOI:10.1007/s10067-020-05160-x
COVID-19 with rheumatic diseases: a report of 5 cases.
Cheng C[SUP]1[/SUP], Li C[SUP]1[/SUP], Zhao T[SUP]1[/SUP], Yue J[SUP]1[/SUP], Yang F[SUP]2[/SUP], Yan Y[SUP]3,[/SUP][SUP]4,[/SUP][SUP]5[/SUP], Liu X[SUP]6,[/SUP][SUP]7[/SUP].
Author information
Abstract
The coronavirus disease 2019 (COVID-19), the result of an infection with the new virus, SARS-CoV-2, is rapidly spreading worldwide. It is largely unknown whether the occurrence of COVID-19 in patients with rheumatic immune diseases has some specific manifestations, or makes them more prone to rapidly progress into severe COVID-19. In this case report, we describe the clinical features of 5 rheumatic immune disease patients with the concomitant presence of COVID-19. Amongst these patients, 4 had rheumatoid arthritis (RA) and 1 had systemic sclerosis (SSc). Two patients had a history of close contact with a COVID-19 patient. The age of the patients ranged between 51 and 79 years. Fever (80%), cough (80%), dyspnea (40%), and fatigue (20%) were the most common presenting symptoms. Laboratory investigations revealed leukopenia and lymphopenia in 2 patients. In all the patients, chest computerized tomography (CT) revealed patchy ground glass opacities in the lungs. During the hospital stay, the condition of two patients remained the same (i.e., mild COVID-19), two patients progressed to the severe COVID-19, and one patient worsened to the critically ill COVID-19. These patients were treated with antiviral agents for COVID-19, antibiotics for secondary bacterial infections, and immunomodulatory agents for rheumatic immune diseases. All the patients responded well, were cured of COVID-19, and subsequently discharged.
KEYWORDS:
COVID-19; Coronavirus; Rheumatic immune disease; SARS-CoV-2
PMID:32406001DOI:10.1007/s10067-020-05160-x